AU2014228166A1 - Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors - Google Patents

Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors Download PDF

Info

Publication number
AU2014228166A1
AU2014228166A1 AU2014228166A AU2014228166A AU2014228166A1 AU 2014228166 A1 AU2014228166 A1 AU 2014228166A1 AU 2014228166 A AU2014228166 A AU 2014228166A AU 2014228166 A AU2014228166 A AU 2014228166A AU 2014228166 A1 AU2014228166 A1 AU 2014228166A1
Authority
AU
Australia
Prior art keywords
egfr
mir
cancer
erlotinib
tki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014228166A
Other languages
English (en)
Inventor
Andreas Bader
Kevin Kelnar
Jane Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Mirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirna Therapeutics Inc filed Critical Mirna Therapeutics Inc
Publication of AU2014228166A1 publication Critical patent/AU2014228166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014228166A 2013-03-15 2014-03-14 Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors Abandoned AU2014228166A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361787558P 2013-03-15 2013-03-15
US61/787,558 2013-03-15
US201461927543P 2014-01-15 2014-01-15
US61/927,543 2014-01-15
PCT/US2014/028006 WO2014143855A2 (fr) 2013-03-15 2014-03-14 Traitements combinés du cancer à l'aide de micro-arn et d'inhibiteurs d'egfr-tki

Publications (1)

Publication Number Publication Date
AU2014228166A1 true AU2014228166A1 (en) 2015-09-24

Family

ID=50678292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014228166A Abandoned AU2014228166A1 (en) 2013-03-15 2014-03-14 Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors

Country Status (11)

Country Link
US (2) US20140309278A1 (fr)
EP (1) EP2968567A2 (fr)
JP (1) JP2016519076A (fr)
KR (1) KR20150131312A (fr)
CN (1) CN105263523A (fr)
AU (1) AU2014228166A1 (fr)
BR (1) BR112015023439A2 (fr)
CA (1) CA2903882A1 (fr)
EA (1) EA201591543A1 (fr)
MX (1) MX2015013177A (fr)
WO (1) WO2014143855A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
KR20160122850A (ko) * 2014-02-28 2016-10-24 미르나 테라퓨틱스 인코포레이티드 간암에 대한 소라페닙-마이크로rna 병용 요법
WO2016161196A1 (fr) * 2015-04-03 2016-10-06 Mirna Therapeutics, Inc. Immunothérapie faisant intervenir le microarn-34
KR20180021736A (ko) * 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 세포의 항아폽토시스, 생존, 또는 증식을 유도하기 위한 조성물 및 방법
KR101876724B1 (ko) * 2016-05-09 2018-07-13 주식회사 싸이토젠 폐암 환자의 혈중 순환 종양세포를 활용한 egfr-tki 내성 환자의 맞춤형 항암제 선별시스템 및 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
WO2019103578A1 (fr) * 2017-11-27 2019-05-31 (주)프로스테믹스 Oligonucléotide et composition pharmaceutique le comprenant pour la prévention ou le traitement du cancer
US11492671B2 (en) 2018-04-11 2022-11-08 Istituti Fisioterapici Ospitalieri MiRNAs for treatment and in vitro diagnosis of drug resistant tumors
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN114025772A (zh) * 2019-04-24 2022-02-08 纪念斯隆凯特琳癌症中心 用于治疗ras突变体癌症的组合物和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
WO2005013901A2 (fr) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
CA2689974A1 (fr) * 2007-06-08 2008-12-18 Asuragen, Inc. Genes et chemins regules par mir-34 en tant que cibles pour une intervention therapeutique
CN102112110A (zh) 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 用于RNAi试剂体内递送的新型组合物
WO2011059752A1 (fr) * 2009-10-28 2011-05-19 Board Of Regents Of The University Of Texas System Procédés et compositions pour un traitement anti-egfr
ES2608923T3 (es) * 2009-11-24 2017-04-17 The University Of Western Australia Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa
RU2615117C2 (ru) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. ДВУХЦЕПОЧЕЧНАЯ МОЛЕКУЛА РНК ДЛЯ ОБЕСПЕЧЕНИЯ КЛЕТКИ АКТИВНОСТЬЮ miR-34a
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
KR20140069331A (ko) * 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ＥｒｂＢ3 항체 및 이의 용도
CA2858382A1 (fr) * 2011-12-10 2013-06-13 Ohio State Innovation Foundation Miarn utiles pour reduire la tumorigenese du cancer du poumon et compositions et methodes associees

Also Published As

Publication number Publication date
EP2968567A2 (fr) 2016-01-20
CA2903882A1 (fr) 2014-09-18
WO2014143855A3 (fr) 2014-12-04
BR112015023439A2 (pt) 2017-07-18
JP2016519076A (ja) 2016-06-30
MX2015013177A (es) 2016-10-03
EA201591543A1 (ru) 2016-09-30
US20150272981A1 (en) 2015-10-01
WO2014143855A2 (fr) 2014-09-18
KR20150131312A (ko) 2015-11-24
US20140309278A1 (en) 2014-10-16
CN105263523A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
AU2014228166A1 (en) Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors
Principe et al. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy
Zhao et al. In-depth analysis shows synergy between erlotinib and miR-34a
Sen et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer
US20170035797A1 (en) Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
Shah et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer
Takebe et al. Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Awad et al. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
US20160160213A1 (en) Methods of treating cancer and preventing cancer drug resistance
JP2016520528A (ja) 癌の治療及び抗癌剤耐性の防止方法
CN104968347A (zh) 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途
Solier et al. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment
WO2015134674A1 (fr) Biomarqueurs de réponse aux thérapies ciblant les kinases 4/6 dépendantes des cyclines dans le cancer
US20230383365A1 (en) Cancer treatments and methods of selecting same
Patel et al. Personalizing chemotherapy dosing using pharmacological methods
EP3727385A1 (fr) Méthodes et polythérapie pour traiter le cancer
Chilamakuri et al. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy
Liu et al. Emerging roles of m6A RNA modification in cancer therapeutic resistance
US20160136181A1 (en) Microrna dosing regimens
US9334500B2 (en) Methods and pharmaceutical compositions for treating cancer
Jang et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models
Chen et al. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment
Brand et al. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
Patsouris et al. Benefits versus risk profile of buparlisib for the treatment of breast cancer
KR20190099253A (ko) 단백질 키나제 억제제 및 추가 화학요법제의 조합물

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period